Remerciez-le!

Remerciez @Admin pour avoir partagé cet document gratuitement, de la manière la plus simple, en partageant sur les réseaux sociaux.

See discussions, stats, and author profiles for this publication at: https://ww

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/271384572 Recurrent ear infections in children Article · December 2014 CITATIONS 0 READS 253 1 author: Some of the authors of this publication are also working on these related projects: Logan Turners Diseases of the Throat, Nose and Ear View project Research Paper View project M-L Montague NHS Lothian 41 PUBLICATIONS 270 CITATIONS SEE PROFILE All content following this page was uploaded by M-L Montague on 15 March 2016. The user has requested enhancement of the downloaded file. Journal of ENT masterclass ISSN 2047-959X Journal of ENT MASTERCLASS® Y ear Book 2014 Volume 7 Number 1 for LPR LPRadvice.co.uk See how it works: LPRadvice.co.uk/demo JOINT ESSENTIAL INFORMATION Gaviscon Advance Peppermint Flavour Oral Suspension, Gaviscon Advance Aniseed Suspension, Gaviscon Advance Mint Chewable Tablets. Active substances Gaviscon Advance Peppermint Flavour,Gaviscon Advance Aniseed Suspension: Each 5 ml dose contains sodium alginate 500.0mg and potassium hydrogen carbonate 100.0mg Gaviscon Advance Mint Chewable Tablets: Sodium alginate 500 mg and Potassium bicarbonate 100 mg per tablet. Indications: Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. Can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy. Dosage Instructions: Gaviscon Advance Peppermint Flavour Oral Suspension, Gaviscon Advance Aniseed Suspension: Adults and children 12 years and over: 5-10 ml after meals and at bedtime (one to two 5 ml measuring spoons). Gaviscon Advance Mint Chewable Tablets: For oral administration after being thoroughly chewed. Adults and children 12 years and over: One to two tablets after meals and at bedtime. Children under 12 years: Should be given only on medical advice. Elderly: No dose modification is required for this age group Contraindications: Hypersensitivity to any of the ingredients, including the esters of hydroxybenzoates (parabens). Precautions and Warnings: Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. There is a possibility of reduced efficacy in patients with very low levels of gastric acid.Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.If symptoms do not improve after seven days, the clinical situation should be reviewed. Gaviscon Advance Peppermint Flavour Oral Suspension, Gaviscon Advance Aniseed Suspension: Each 10 ml dose has a sodium content of 106 mg (4.6mmol) and a potassium content of 78 mg (2.0 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs which can increase plasma potassium levels. Each 10 ml contains 200 mg (2.0 mmol) of calcium carbonate. This medicinal product contains Methyl hydroxybenzoate and Propyl hydroxybenzoate, which may cause allergic reactions (possibly delayed). Gaviscon Advance Mint Chewable Tablets: Each two-tablet dose has a sodium content of 103mg (4.5mmol) and a potassium content of 78mg (2.0mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs which can increase plasma potassium levels. Each two-tablet dose contains 200 mg (2.0 mmol) of calcium carbonate. Gaviscon Advance Tablets may cause central nervous system depression in the presence of renal insufficiency and should not be used in patients with renal failure. Due to its aspartame content this product should not be given to patients with phenylketonuria. Side-Effects: Very rarely (<1/10,000) patients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions. NHS List Price: Gaviscon Advance Peppermint Flavour Oral Suspension: 250ml - £2.56, 500ml - £5.12 Gaviscon Advance Aniseed Suspension: 250ml - £2.56, 500ml - £5.12 Gaviscon Advance Mint Chewable Tablets: 60 Tablets - £3.07 Marketing Authorisation: Gaviscon Advance Peppermint Flavour Oral Suspension- PL 00063/0612 Gaviscon Advance Aniseed Suspension - PL 00063/0108. Gaviscon Advance Mint Chewable Tablets – PL 00063/613 Supply Classification Gaviscon Advance Peppermint Flavour Oral Suspension/ Gaviscon Advance Aniseed Suspension - P Gaviscon Advance Mint Chewable Tablets - GSL Marketimng authorisation Holder: Reckitt Benckiser Healthcare (UK) Limited, Dansom Lane, Hull, HU8 7DS. Gaviscon and the sword and circle symbol are trade marks. Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk/yellowcard Adverse events should also be reported to Reckitt Benckiser on 0500 455 456. Date of preparation: June 2013 UK/G-NHS/0613/0027 Gaviscon Advance Peppermint Suspension (sodium alginate, potassium hydrogen carbonate) and Gaviscon Advance Mint Chewable Tablets (sodium alginate, potassium bicarbonate). Also Available: for LPR LPRadvice.co.uk See how it works: LPRadvice.co.uk/demo JOINT ESSENTIAL INFORMATION Gaviscon Advance Peppermint Flavour Oral Suspension, Gaviscon Advance Aniseed Suspension, Gaviscon Advance Mint Chewable Tablets. Active substances Gaviscon Advance Peppermint Flavour,Gaviscon Advance Aniseed Suspension: Each 5 ml dose contains sodium alginate 500.0mg and potassium hydrogen carbonate 100.0mg Gaviscon Advance Mint Chewable Tablets: Sodium alginate 500 mg and Potassium bicarbonate 100 mg per tablet. Indications: Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. Can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy. Dosage Instructions: Gaviscon Advance Peppermint Flavour Oral Suspension, Gaviscon Advance Aniseed Suspension: Adults and children 12 years and over: 5-10 ml after meals and at bedtime (one to two 5 ml measuring spoons). Gaviscon Advance Mint Chewable Tablets: For oral administration after being thoroughly chewed. Adults and children 12 years and over: One to two tablets after meals and at bedtime. Children under 12 years: Should be given only on medical advice. Elderly: No dose modification is required for this age group Contraindications: Hypersensitivity to any of the ingredients, including the esters of hydroxybenzoates (parabens). Precautions and Warnings: Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. There is a possibility of reduced efficacy in patients with very low levels of gastric acid.Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.If symptoms do not improve after seven days, the clinical situation should be reviewed. Gaviscon Advance Peppermint Flavour Oral Suspension, Gaviscon Advance Aniseed Suspension: Each 10 ml dose has a sodium content of 106 mg (4.6mmol) and a potassium content of 78 mg (2.0 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs which can increase plasma potassium levels. Each 10 ml contains 200 mg (2.0 mmol) of calcium carbonate. This medicinal product contains Methyl hydroxybenzoate and Propyl hydroxybenzoate, which may cause allergic reactions (possibly delayed). Gaviscon Advance Mint Chewable Tablets: Each two-tablet dose has a sodium content of 103mg (4.5mmol) and a potassium content of 78mg (2.0mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs which can increase plasma potassium levels. Each two-tablet dose contains 200 mg (2.0 mmol) of calcium carbonate. Gaviscon Advance Tablets may cause central nervous system depression in the presence of renal insufficiency and should not be used in patients with renal failure. Due to its aspartame content this product should not be given to patients with phenylketonuria. Side-Effects: Very rarely (<1/10,000) patients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions. NHS List Price: Gaviscon Advance Peppermint Flavour Oral Suspension: 250ml - £2.56, 500ml - £5.12 Gaviscon Advance Aniseed Suspension: 250ml - £2.56, 500ml - £5.12 Gaviscon Advance Mint Chewable Tablets: 60 Tablets - £3.07 Marketing Authorisation: Gaviscon Advance Peppermint Flavour Oral Suspension- PL 00063/0612 Gaviscon Advance Aniseed Suspension - PL 00063/0108. Gaviscon Advance Mint Chewable Tablets – PL 00063/613 Supply Classification Gaviscon Advance Peppermint Flavour Oral Suspension/ Gaviscon Advance Aniseed Suspension - P Gaviscon Advance Mint Chewable Tablets - GSL Marketimng authorisation Holder: Reckitt Benckiser Healthcare (UK) Limited, Dansom Lane, Hull, HU8 7DS. Gaviscon and the sword and circle symbol are trade marks. Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk/yellowcard Adverse events should also be reported to Reckitt Benckiser on 0500 455 456. Date of preparation: June 2013 UK/G-NHS/0613/0027 Gaviscon Advance Peppermint Suspension (sodium alginate, potassium hydrogen carbonate) and Gaviscon Advance Mint Chewable Tablets (sodium alginate, potassium bicarbonate). Also Available: Innovating for life. TriVantage | APS | NIM 3.0 Confidence Security Safety UC201403300EE 1 Y E A R B O O K 2 0 1 4 uploads/Sante/ ent-journal-vol7-2014.pdf